Drug Target Review

Pomegranate-derived compound shows therapeutic potential in heart disease

2026-06-15T07:00:00+01:00Contributor Professor Dipak Ramji, By Drug Target Review

Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a potential new approach for treating cardiovascular disease. Their findings suggest the molecule could help reduce inflammation and stabilise dangerous artery plaques, potentially lowering the risk of heart attacks and strokes.

Article
AACR 2026 part two: integrating AI, spatial biology and next-gen therapeutics
2026-06-11T12:00:00+01:00By Sam Wightwick
In part two of our AACR 2026 coverage, industry leaders were focussed on how the field is no longer constrained by data generation or molecular design, but by the challenge of connecting systems, standardising workflows and ensuring biological insights.
Report
AI in Drug Discovery: Progress, Limits and What Comes Next
2026-06-10T09:22:00+01:00By Drug Target Review
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
Article
Why scaling human-derived models is pharma’s next big challenge
2026-06-09T08:20:00+01:00Contributor Steve Smith, By Drug Target Review
Many drugs still fail after promising preclinical results, raising difficult questions about how disease is modelled in the lab. Researchers are now turning to organoids and iPSC-derived systems to build more predictive models for drug discovery and reduce costly late-stage failures.

Opinion and interviews

Computational design drives new generation of synthetic promoters

2026-03-26T14:21:00+00:00By Drug Target Review

Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.

Webinar

Where NAMs stand in early drug discovery: an expert discussion

From expert task to lab routine – Membrane protein purification and analysis simplified

Sponsored by Analytik Jena GmbH + Co. KG

A new way to tackle the most challenging drug targets: Discover a fully automated, detergent-free purification workflow that isolates membrane proteins in their native 3D structure in as little as three hours and with minimal hands-on time. Learn how to perform subsequent digital miniaturization and qPCR-based stability analysis with compact solutions that integrate seamlessly into your lab.